News & Press

CDMO Expands US Peptide Manufacturing Capacity

July 07, 2020
Press Release > CordenPharma Increases US Peptide Manufacturing Capacity to Accommodate Global Market Growth

Press Release > CordenPharma Increases US Peptide Manufacturing Capacity to Accommodate Global Market Growth

Luxembourg, 7 July 2020

CordenPharma is proud to announce peptide manufacturing capacity expansion in CordenPharma Colorado, their GMP API facility in Boulder, CO (US). Already known for its unique large-scale peptide offering with a 10’000 L SPPS (Solid-Phase Peptide Synthesis) vessel, and a 100 cm high-pressure reverse phase purification column, CordenPharma Colorado is recognized as the largest worldwide peptide API producer leading the global peptide market.

In order to accommodate a large spike in the demand for peptide APIs, and to continue an overall growth strategy, CordenPharma Colorado recently completed expansion of their solid-phase peptide manufacturing capacity. Dr. Matthieu Giraud, Director, Global Peptides, Lipids & Carbohydrates Platform, explains: “With the addition of this extra-large 3’000 L SPPS vessel, our assembly-time, capacity and flexibility has been significantly increased, reinforcing CordenPharma Colorado as the current large-scale peptide manufacturing capacity leader. This new asset gives us the ability to manufacture a complex long peptide with a 400 kg output per single batch. Our team in Colorado aims to utilize this new capacity to conduct validation campaigns designed to support customer projects with a global impact.”

Large-scale Peptide Manufacturing Expansion in CordenPharma Colorado (US)

Large-scale Peptide Manufacturing Expansion in CordenPharma Colorado (US).

CordenPharma has over 130 years of cumulative experience across its global facility network in the US & Europe, which allows for a high-level of response to growing local demand at the country and community level, particularly during the recent COVID-19 pandemic.

With approximately 300 employees, CordenPharma Colorado has grown a strong focus in the development & manufacturing of APIs from laboratory-scale to commercialization at ton-scale, due to their unique large-scale SPPS capabilities. The purification of the final peptide is performed at any scale in columns ranging from 5 cm to 100 cm. To avoid the tedious and poor productivity of the final isolation step by lypohilization, their development team gained an unmatched expertise in peptide precipitation that successfully transferred to production in commercial products. The site has a long track record in large-scale manufacturing, where all potencies, including picogram levels, can be reached.

About CordenPharma

CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a growing network of cGMP facilities across Europe and the US organized under four Technology Platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, and Small Molecules – CordenPharma experts translate complex processes and projects at any stage of development into high-value products.


Contact us for more information

Read Press Release Pdf